1. Home
  2. CRBP vs ACHV Comparison

CRBP vs ACHV Comparison

Compare CRBP & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • ACHV
  • Stock Information
  • Founded
  • CRBP 2009
  • ACHV N/A
  • Country
  • CRBP United States
  • ACHV United States
  • Employees
  • CRBP N/A
  • ACHV N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • CRBP Health Care
  • ACHV Health Care
  • Exchange
  • CRBP Nasdaq
  • ACHV Nasdaq
  • Market Cap
  • CRBP 110.3M
  • ACHV 131.2M
  • IPO Year
  • CRBP N/A
  • ACHV N/A
  • Fundamental
  • Price
  • CRBP $8.90
  • ACHV $2.62
  • Analyst Decision
  • CRBP Strong Buy
  • ACHV Strong Buy
  • Analyst Count
  • CRBP 10
  • ACHV 3
  • Target Price
  • CRBP $53.56
  • ACHV $14.33
  • AVG Volume (30 Days)
  • CRBP 124.3K
  • ACHV 1.1M
  • Earning Date
  • CRBP 08-05-2025
  • ACHV 08-07-2025
  • Dividend Yield
  • CRBP N/A
  • ACHV N/A
  • EPS Growth
  • CRBP N/A
  • ACHV N/A
  • EPS
  • CRBP N/A
  • ACHV N/A
  • Revenue
  • CRBP N/A
  • ACHV N/A
  • Revenue This Year
  • CRBP N/A
  • ACHV N/A
  • Revenue Next Year
  • CRBP $270.04
  • ACHV N/A
  • P/E Ratio
  • CRBP N/A
  • ACHV N/A
  • Revenue Growth
  • CRBP N/A
  • ACHV N/A
  • 52 Week Low
  • CRBP $4.64
  • ACHV $1.84
  • 52 Week High
  • CRBP $61.89
  • ACHV $5.31
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 53.56
  • ACHV 47.41
  • Support Level
  • CRBP $9.10
  • ACHV $2.52
  • Resistance Level
  • CRBP $9.80
  • ACHV $2.75
  • Average True Range (ATR)
  • CRBP 0.62
  • ACHV 0.13
  • MACD
  • CRBP 0.01
  • ACHV 0.02
  • Stochastic Oscillator
  • CRBP 31.45
  • ACHV 33.33

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

Share on Social Networks: